Home|Journals|Articles by Year|Audio Abstracts
 

Short Communication

RMJ. 2016; 41(4): 519-521


Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients

Osama Ishtiaq, Rida Kamal, Tahir Iqbal, Batool Zehra.




Abstract

Objective: We evaluated the use of Exenatide in terms of weight reduction and improvement of glycemic control, in patients with type 2 diabetes and obesity from Pakistan. Methodology: The study was done in Shifa International Hospital, Islamabad from year 2013 to 2014. Exenatide was prescribed to 45 patients, in which 19 patients had completed follow-ups. HbA1c, BMI and weight were recorded before and after the treatment. Side effects and reason for early discontinuation were also noted. Results: The concurrent use of Exenatide along with other anti-diabetic medications, enabled patients to reduce an average weight of 6.6kg (average decrease in BMI was 1.82kg/m2) and HbA1c levels of 0.6% over a period of 5 months, making it a promising therapeutic agent in obese and diabetic patients. The most common side effect noted was nausea. Conclusion: Exenatide has a potential to achieve reasonable weight loss and mild improvements in glycemic control in Pakistani obese and diabetic patients.

Key words: Exenatide, diabetes mellitus, obesity, GLP-1 agonist






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.